Caspofungin: Indications and Dosing
Caspofungin is indicated for invasive candidiasis (including candidemia), invasive aspergillosis (salvage therapy), and empirical therapy in febrile neutropenic patients, with standard adult dosing of 70 mg loading dose followed by 50 mg daily—and critically, dose reduction to 35 mg daily for moderate hepatic impairment (Child-Pugh B) is NOT recommended based on recent real-world evidence showing this results in subtherapeutic exposure. 1, 2
FDA-Approved Indications
Caspofungin is approved for 1:
- Candidemia and other Candida infections (intra-abdominal abscesses, peritonitis, pleural space infections)
- Esophageal candidiasis
- Invasive aspergillosis (in patients refractory to or intolerant of other therapies)
- Empirical therapy for presumed fungal infections in febrile neutropenic patients
Standard Adult Dosing
Most Indications (Candidemia, Invasive Aspergillosis, Empirical Therapy)
- Loading dose: 70 mg IV on Day 1
- Maintenance dose: 50 mg IV once daily
- Duration: Varies by indication 1
- Candidemia: ≥14 days after last positive culture and resolution of symptoms
- Invasive aspergillosis: Based on disease severity, immunosuppression recovery, and clinical response
- Empirical therapy: Until neutropenia resolution; minimum 14 days after positive culture if fungal infection confirmed
Esophageal Candidiasis
- No loading dose
- Maintenance dose: 50 mg IV once daily
- Duration: 7-14 days after symptom resolution 1
Dose Escalation
If 50 mg is well-tolerated but clinically inadequate, increase to 70 mg daily 1
Pediatric Dosing (3 months to 17 years)
Body surface area (BSA)-based dosing 1:
- Loading dose: 70 mg/m² on Day 1 (maximum 70 mg)
- Maintenance dose: 50 mg/m² once daily (maximum 70 mg)
- Can escalate to 70 mg/m² daily if inadequate response (maximum 70 mg)
Critical caveat: Insufficient data for neonates <3 months; caspofungin has not been studied for pediatric endocarditis, osteomyelitis, or meningitis 1
Hepatic Impairment Dosing: The Controversy Resolved
FDA Label Recommendation vs. Current Evidence
The FDA label recommends dose reduction to 35 mg daily for moderate hepatic impairment (Child-Pugh B) after a 70 mg loading dose 1. However, multiple recent high-quality studies demonstrate this is inappropriate and leads to treatment failure.
Evidence-Based Recommendation
Do NOT reduce the dose in Child-Pugh B or C cirrhosis 3, 4, 2:
- Child-Pugh A (score 5-6): Standard dosing (70/50 mg)
- Child-Pugh B (score 7-9): Standard dosing (70/50 mg) despite FDA label
- Child-Pugh C (score >9): Standard dosing (70/50 mg)
Rationale:
- A 2018 pharmacokinetic study showed only marginal reduction in caspofungin clearance in decompensated Child-Pugh B/C cirrhosis 2
- Dose reduction to 35 mg resulted in significantly lower drug exposure than standard dosing in non-cirrhotic patients 2
- A 2016 ICU study demonstrated that 35 mg maintenance dose in Child-Pugh B patients resulted in suboptimal exposure and only 14% pharmacokinetic target attainment at MIC 0.125 µg/mL 5
- Real-world studies from 2022-2024 involving 458 cirrhotic patients (Child-Pugh B and C) showed standard-dose caspofungin was safe and effective without hepatic function deterioration 3, 4
Important distinction: The Child-Pugh score in ICU patients is often driven by hypoalbuminemia rather than true cirrhosis—dose reduction in this context is particularly inappropriate 5, 2
Drug Interactions Requiring Dose Adjustment
Enzyme Inducers (Increase Caspofungin Clearance)
Adults: Increase to 70 mg daily when co-administered with 1:
- Rifampin (mandatory adjustment)
- Efavirenz, nevirapine, carbamazepine, dexamethasone, phenytoin (consider adjustment)
Pediatrics: Increase to 70 mg/m² daily (maximum 70 mg) with same inducers 1
Renal Impairment
No dose adjustment required for any degree of renal impairment, including hemodialysis (caspofungin is not dialyzable) 1
Administration
- Infuse over approximately 1 hour via slow IV infusion
- Never give as IV bolus 1
- Reconstitute with 10.8 mL diluent (0.9% NaCl, sterile water, or bacteriostatic water)
Therapeutic Drug Monitoring
Consider TDM-guided dosing in high-risk populations 6:
- Premature neonates
- Critically ill patients with altered volume of distribution
- Patients on extracorporeal circuits
- Severe hypoalbuminemia
- Morbidly obese patients
- Treatment failure cases
Target trough concentration (Cmin): >1 mg/L for acceptable exposure 6; recent data suggests >3.58 µg/mL may optimize clinical efficacy 7
Guideline-Based Clinical Context
The 2016 IDSA guidelines support echinocandins (including caspofungin) as preferred empiric therapy for suspected candidiasis in ICU patients 8. For candidemia, continue therapy ≥14 days after last positive culture 8. The 2025 ECMM global guideline emphasizes source control (catheter removal) and therapeutic drug monitoring where available 6.
Critical pitfall: Body weight significantly impacts caspofungin exposure—patients ≥70 kg may require higher doses (70 mg maintenance) to achieve adequate drug levels 5, 9, 7